SCHEMBL317866

SCHEMBL317866

COc1ccc(C2=Cc3cc(OC)ccc3C3CCCCC23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.44
NOS1 P29475 2/20 0.44
NOS2 P35228 2/20 0.44
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
PDE4D Q08499 2/20 0.36
FDFT1 P37268 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
PTGS2 P35354 1/20 0.35
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
APP P05067 1/20 0.34
ABL1 P00519 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10109013 1.00 NOS3 (0.44) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL317860 0.89 NOS3 (0.44) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL10108826 0.89 NOS3 (0.44) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL10108856 0.86 NOS3 (0.47) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL317663 0.86 NOS3 (0.47) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL317877 0.77 HCRTR1 (0.38) PDE4APDE4BPDE4CPDE4DABCB1
SCHEMBL10108986 0.77 HCRTR1 (0.38) PDE4APDE4BPDE4CPDE4DABCB1
SCHEMBL3639292 0.76 BACE1 (0.43) MEN1KMT2APDE4APDE4BPDE4C
SCHEMBL10109229 0.76 NPC1 (0.39) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL10108934 0.75 KDM1A (0.39) NOS3NOS1NOS2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed
EP-1853578-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2007-11-14 EP disclosed
WO-2006088716-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ESR2, ERLIN1, ESRRG NOS3 3463/4885NOS1 3050/4885NOS2 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.